SCHOTT Pharma Extends CEO Andreas Reisse’s Tenure to 2026 While Appointing Reinhard Mayer as CFO

SCHOTT Pharma Extends CEO Andreas Reisse’s Tenure to 2026 While Appointing Reinhard Mayer as CFO

(IN BRIEF) SCHOTT Pharma’s Supervisory Board has prolonged CEO Andreas Reisse’s mandate until April 2026, reflecting his pivotal role in driving the company’s emergence as a world-leading manufacturer of pharmaceutical containment and delivery systems. CFO Dr. Almuth Steinkühler will step down on July 31, 2025, having steered the company through its IPO and established key financial processes. Reinhard Mayer—an industrial engineering graduate with extensive CFO experience at Nilfisk, Hansgrohe and Getinge—will take over as CFO on August 1, 2025. Board chairman Peter Goldschmidt lauded both Steinkühler’s contributions and Mayer’s proven track record, while Reisse and Mayer expressed enthusiasm for the company’s ambitious growth plans and commitment to innovation in the pharmaceutical arena.

(PRESS RELEASE) MAINZ, 11-Jun-2025 — /EuropaWire/ — The Supervisory Board of SCHOTT Pharma Management AG has extended Andreas Reisse’s term as Chief Executive Officer through April 2026, in line with the mandatory retirement age of 65 set out in the Articles of Association. Mr. Reisse, who has worked at the SCHOTT Group since 1987 and has overseen the Pharmaceutical Systems division since 2010 (now publicly traded on the Frankfurt Stock Exchange as SCHOTT Pharma AG & Co. KGaA), has been instrumental in positioning the company as a global leader in pharmaceutical containment and delivery solutions. “We are delighted that Andreas will continue to drive SCHOTT Pharma’s innovation and sustained growth, expanding our footprint worldwide,” said Peter Goldschmidt, Chairman of the Supervisory Board.

“I’m grateful for the Board’s confidence,” remarked Andreas Reisse. “Together, we’ve delivered pioneering breakthroughs, achieved record growth and advanced patient health sustainably. There is much more ahead, and I look forward to working with our talented team on our ambitious plans.”

Concurrently, CFO Dr. Almuth Steinkühler announced she will not seek a contract renewal and will depart on July 31, 2025, to pursue new challenges. Peter Goldschmidt paid tribute to her leadership in preparing SCHOTT Pharma for its IPO, establishing robust processes and enhancing investor trust. “Almuth’s expertise and foresight have been vital to our capital-market success and strategic development,” he said.

Effective August 1, 2025, Reinhard Mayer will assume the role of CFO. An industrial engineering graduate with over two decades in senior finance, controlling and IT positions, Mr. Mayer joins from Nilfisk Holding A/S (CFO) and brings previous CFO tenures at Hansgrohe SE and Getinge Group, where he drove organic growth strategies, financial consolidation, process digitisation and M&A projects. “We’re pleased to welcome Reinhard, whose financial acumen and leadership will be key to advancing SCHOTT Pharma’s trajectory as a listed company,” Goldschmidt added.

Reinhard Mayer commented: “I appreciate the Board’s trust. SCHOTT Pharma’s impressive performance, growth prospects and dynamic team make this an exciting opportunity. I look forward to contributing to our continued success in one of the fastest-growing pharmaceutical sectors.”

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

Media Contact:

Lea Kaiser
PR & Communications Manager
+49 (0) 6131 66-2422

SOURCE: SCHOTT Pharma